Member Info for Jarv55

Knee agree with you it stinks that they went with a show of hands they should respect shareholders wishes we don't want to be diluted into oblivion. If they want to raise it has to be at a lot higher than 0.00020

mcrummett I think you need a sense of humour to hold Nyo and Moz clearly has one

Should know by 8 in the morning how the vote went I hope everyone voted against the 400 to 1 consolidation

Try looking on a pc

Investor Relations‏ @bigdishIR Looking forward to the NYO EGM on Monday #NYO

Bought a few of these today strange the mms have put buys through as sells

Not many Aim companies making profit might even get a mention in the papers

Supercare Group Ghana 84.16 m 9.8 m COFCO China 92.11 m 10.8 m YinshanHongzhan Industry Co., Ltd China 23.49 m 2.8 m Inner Mongolia Liniu Biochemical Co., Ltd China 13.5 m 1.6 m Jilin Boda Biochemical Co. Ltd China 76.04 m 8.9 m Heilongjiang WeiketeBiotechnology Co., Ltd China 1.8 m 0.2m Products and Services The Group principally provides EPC (Equipment, Procurement and Construction) services and VAS (Value Added Services) to ethanol and biobutanol producers. The EPC team primarily design and build commercial-scale biorefineries that convert feedstock into ethanol for both the biofuel and edible alcohol markets, whilst the VAS team provide services and technology to optimise the ethanol production at existing biorefineries. CNE is a market leader in China at designing and building biorefineries that convert agricultural feedstock such as corn, cassava and sugarcane into ethanol for the fuel and food sectors. We have completed significantly more than 150 projects in China and around the world. The market is now evolving as our customers in China and other developed nations seek to broaden the range of feedstocks to include non-food materials such as corn stover and municipal waste in 2nd Generation biorefineries. As a market leader in ethanol process technologies CNE is actively exploring the array of 2G technologies which are nearing commercialisation in order to extend the Company's solutions to respond to this important market trend.

For the year ended 31 December 2016, the Group's total revenue was RMB78.6 million (c. £9.2million), an increase of 27.4% from RMB 61.7 million (c. £6.4million). We are pleased to report that CNE has returned to profitability and that the business outlook is for continued and sustained growth. The return to profitability is a direct result of our decision to diversify into new technologies and markets such as our contract with BioNeutra North America Inc for a isomaltooligosaccharide production line (RMB 11.2m), and contracts in China with existing customers such as the anhydrous ethanol EPC contract with Jilin Buoda alcohol group (RMB17 million), the implementation of our Shandong Hongda super grade alcohol project (RMB10.7) and several other small and medium-sized projects. The gross profit for the year was RMB27 million (c. £3.2 million) up 252% from a gross profit of RMB7.7 million (c. £0.8 million). For the year 2016, the company recorded a profit of RMB 3.6million (c. £0.4 million) reversing the previous net loss of RMB25.6 million (c. £2.7 million). Sales Pipeline We enter 2017 with a strong order book of RMB 292.7 million (c. £26.6 million) which we attribute to the implementation of a strategy to focus on international markets, the diversification of our products, and to renewed growth in the Chinese market that is driven by China's revised ethanol policy. The latter is the consequence of a relaxation of Chinese legislation to restrict the use of corn as a feedstock for ethanol production, which had been in place since 2006, and the resultant increase in corn-based ethanol projects in northern China. Notable contracts include:

Bid is rising back up Andy that was your bottom

Or directors might buy some shares now there isn't a closed period and it could shoot up

Well I bought more market will wake up in the next couple of sessions

That is the gap closed onwards and upwards

The gross profit for the year was RMB27 million (c. £3.2 million) up 252% from a gross profit of RMB7.7 million (c. £0.8 million).

This should be 3-4p

Fantastic rns well done holders and management

Recovery back to 16p by next year

Looks good to me 47% increase in new customers https://www.**********.co.uk/rns/announcement/26125262/?source=twitter

Post from Advfn Dusseldorf 28 Jun '17 - 18:54 - 1175 of 1176 1 0 Bionictwat - The business is well en-route to recovery (hopefully the numbers will back up this assumption across the board:revenue up 40%+, NAV up, customers up, costs down, which is based on past updates). The SP in still near 'all time' lows and still undervalued IMO as cash alone is higher. Whether or not a P&D occurs simultaneously is irrelevant ultimately to price direction. Interest is high and results are due next 2 days. If overseas revenue comes on stream H2 2017/2018 and costs are relatively fixed LCG could be multiple of today's price irrespective of short term momentum and remains an attractive takeover target. I can't see it remaining under the radar much longer - NAV will be circa 4p following debt conversion and the new floor (current NAV 2.5p). Fair price? I'm suggesting 5-6p based on what I'm expecting in results assuming recovery continues.

Don't think the market is expecting anything when you look at the price would like to see a strong forward looking statement saying we will return to profitability in 2018